Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of Daridorexant in Insomnia
NCT03679884Phase 3Completed
- Sponsor
- Idorsia
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of daridorexant in insomnia disorder (5 arms), sponsored by Idorsia. Primary endpoint: Treatment-Emergent Adverse Events at 44 weeks. Started Oct 2018; status: completed.
02
Drugs
daridorexant
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT03679884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679884.